Last reviewed · How we verify

Bacterial infection due to Klebsiella pneumoniae — Treatment Landscape & Competitive Intelligence

Bacterial infection due to Klebsiella pneumoniae (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bacterial infection due to Klebsiella pneumoniae, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Teflaro CEFTAROLINE FOSAMIL AbbVie Cephalosporin Antibacterial 2010-01-01
Avelox moxifloxacin Bayer AG Fluoroquinolone antibiotic (fourth-generation) DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A 1999-12-10
ALATROFLOXACIN ALATROFLOXACIN Pfizer alatrofloxacin 1997-01-01
Levaquin levofloxacin Generic (originally Daiichi Sankyo/J&J) Fluoroquinolone Antibacterial [EPC] CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 1996-12-20
Maxipime CEFEPIME Baxter Cephalosporin Antibacterial 1996-01-01
Maxipime Cefepime Hydrochloride Baxter Cephalosporin Bacterial cell wall peptidoglycan 1996-01-01
Cipro ciprofloxacin Bayer AG Fluoroquinolone antibiotic DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A 1987-10-22
Azactam AZTREONAM Bristol-Myers Squibb Monobactam Antibacterial [EPC] 1986-01-01
Fortaz Ceftazidime Pai Holdings Pharm Third-generation cephalosporin Bacterial cell wall 1985-01-01
Primaxin CILASTATIN Merck & Co. Renal Dehydropeptidase Inhibitor Dipeptidase 1 1985-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 13 drugs in Bacterial infection due to Klebsiella pneumoniae
  2. Bristol-Myers Squibb · 4 drugs in Bacterial infection due to Klebsiella pneumoniae
  3. Merck & Co. · 3 drugs in Bacterial infection due to Klebsiella pneumoniae
  4. Bayer AG · 2 drugs in Bacterial infection due to Klebsiella pneumoniae
  5. Pfizer · 2 drugs in Bacterial infection due to Klebsiella pneumoniae
  6. Baxter · 2 drugs in Bacterial infection due to Klebsiella pneumoniae
  7. Pai Holdings Pharm · 2 drugs in Bacterial infection due to Klebsiella pneumoniae
  8. Bayer Pharmaceuticals Corp · 1 drug in Bacterial infection due to Klebsiella pneumoniae
  9. Assistance Publique - Hôpitaux de Paris · 1 drug in Bacterial infection due to Klebsiella pneumoniae
  10. GSK · 1 drug in Bacterial infection due to Klebsiella pneumoniae
  11. Generic (originally Daiichi Sankyo/J&J) · 1 drug in Bacterial infection due to Klebsiella pneumoniae
  12. Eli Lilly · 1 drug in Bacterial infection due to Klebsiella pneumoniae

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bacterial infection due to Klebsiella pneumoniae:

Cite this brief

Drug Landscape (2026). Bacterial infection due to Klebsiella pneumoniae — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacterial-infection-due-to-klebsiella-pneumoniae. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing